コントロール良好な関節リウマチ患者は分子標的薬か らメトトレキサートを中止して寛解を維持できるか? システマティックレビューとメタ解析
J Rheumatol. 2023;50(1):36–47 doi: 10.3899/jrheum.220152
This systematic review and meta-analysis of studies evaluated the proportion of patients in remission after the dosage of MTX was tapered, and concludes that patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months.